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We have previously shown that populations of skeletal muscle-derived stem cells (MDSCs) exhibit sex-
based differences for skeletal muscle and bone repair, with female cells demonstrating superior engrafting
abilities to males in skeletal muscle while male cells differentiating more robustly toward the osteogenic and
chondrogenic lineages. In this study, we tested the hypothesis that the therapeutic capacity of MDSCs trans-
planted into myocardium is influenced by sex of donor MDSCs or recipient. Male and female MDSCs
isolated from the skeletal muscle of 3-week-old mice were transplanted into recipient male or female dys-
trophin-deficient (mdx) hearts or into the hearts of male SCID mice following acute myocardial infarction.
In the mdx model, no difference was seen in engraftment or blood vessel formation based on donor cell or
recipient sex. In the infarction model, MDSC-transplanted hearts showed higher postinfarction angiogenesis,
less myocardial scar formation, and improved cardiac function compared to vehicle controls. However, sex
of donor MDSCs had no significant effects on engraftment, angiogenesis, and cardiac function. VEGF ex-
pression, a potent angiogenic factor, was similar between male and female MDSCs. Our results suggest that
donor MDSC or recipient sex has no significant effect on the efficiency of MDSC-triggered myocardial
engraftment or regeneration following cardiac injury. The ability of the MDSCs to improve cardiac regenera-
tion and repair through promotion of angiogenesis without differentiation into the cardiac lineage may have
contributed to the lack of sex difference observed in these models.
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INTRODUCTION tissue engineering approaches to repair the injured and
failing human heart.
Cellular cardiomyoplasty is an emerging therapeuticHeart disease is the leading cause of death in the
world, and a recent estimate from the American Heart option that has gained recognition as a strategy to repair
damaged myocardium and potentially reverse many de-Association stated that 1 in 3 American adults have a
form of heart disease (30). Heart disease includes both bilitating heart diseases (3). To date, a wide variety of
cell types have been examined for suitability for cardiaccongenital and acquired cardiomyopathies as well as
other types of damage, including ischemic injury from repair, including skeletal myoblasts (31), smooth muscle
cells (11), fibroblasts (14), resident myocardial progeni-myocardial infarction. For most patients, the final thera-
peutic option for end-stage heart failure is heart trans- tors (20,26), mesenchymal stem cells (1,17), hematopoi-
etic stem cells (2,22), and embryonic stem cells (19).plantation, although this is not always a viable option
due to low organ availability and the comorbidities asso- There have also been numerous clinical trials using cell
transplantation to repair the ischemic heart, but thereciated with long-term immunosuppression (3). Limited
donor organ availability and the low regenerative capac- were low efficiencies of transplanted cell survival and
concerns regarding increased risk of clinical arrhyth-ity of the adult heart following injury (8) has stimulated
both basic science research and clinical trials to validate mias, which continue to be under investigation.
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Recently a population of murine muscle-derived stem (5,18). Based on these results, we hypothesized that
there would also be a sex difference in MDSC-inducedcells (MDSCs) has been shown to have an improved
regenerative capacity in bone and skeletal/cardiac mus- cardiac regeneration, which was supported by a recent
study demonstrating sex differences in mesenchymalcles when compared to satellite cells or myoblasts (25,29).
MDSCs are a unique cell population whose characteris- stem cells for cardiac repair (6). In the current study we
investigated transplantation efficiency of MDSCs intotics, including marker profile, proliferation and differen-
tiation kinetics, and regenerative capacity, are distinct both mdx mice and a SCID mouse model of myocardial
infarction to determine if donor cell sex or recipient sexfrom myoblasts (9,15). After implantation into ischemic
hearts, MDSCs display high levels of engraftment that would influence cardiac engraftment and regeneration/
repair. Our results indicate that cell and host sex is notpersist over time, induce neoangiogenesis, prevent car-
diac remodeling, and elicit significant improvements in a critical factor for cardiac engraftment or repair using
MDSCs.cardiac function (25). A human counterpart to MDSCs
has been isolated based on cell surface markers with the
MATERIALS AND METHODShuman muscle-derived cells coexpressing myogenic and
MDSC Isolationendothelial markers. These cells have been shown to be
better than purely myogenic or endothelial cells for both Muscle-derived stem cells were isolated from the
skeletal muscle repair (37) and cardiac repair following skeletal muscle of 3-week-old normal C57BL mice
myocardial infarction (23). (Jackson) using the modified preplate technique as pre-
The variable results noted following cellular trans- viously described (9,12,29). Mice were anatomically
plantation in most organ systems could be due to a vari- sexed prior to isolation. Both male and female MDSCs
ety of factors, including differences in cell populations (five populations of each) were cultured in proliferation
and treatment regimens, as well as other intrinsic charac- media (PM) containing Dulbecco’s modified Eagle me-
teristics, including the sex of the cells and recipient. The dium (DMEM) (Invitrogen), 10% fetal bovine serum
association between sex and cardiac morbidity and mor- (FBS) (Invitrogen), 10% horse serum, 1% penicillin/
tality is well established. The prognosis for males with streptomycin, and 0.5% chick embryo extract (Accurate
heart disease is worse than in premenopause females (16, Chemical).
36), and cardiovascular disease in women is less com-
Intramyocardial Cell Transplantation to mdx Micemon and has a later average age of onset (4,33). Sex-
related differences in stem cell behavior have been noted The use of animals and the surgical procedures per-
for the efficiency of endothelial progenitor cells colony formed in this study were approved by the Institutional
formation, mesenchymal stem cell activation and func- Animal Care and Use Committee of the Children’s Hos-
tion, MDSC-triggered skeletal muscle repair, and stress- pital of Pittsburgh (protocol 14-06). The mdx mice
triggered MDSC gene expression (6,7,10,13). These re- (C57BL/10ScSn-Dmdmdx) were bred in our institution’s
sults suggest that while the microenvironment plays a animal facility. Cell transplantation into mdx hearts was
critical role in stem cell repair, differences in inherent performed as previously described with less than 1%
stem cell characteristics, including sex, could account mortality (27,28). Briefly, each heart was exposed via a
for some of the outcome variability noted in clinical left thoracotomy, and 1 × 105 MDSCs in 10 µl phos-
trials. Characterizing subtle but clinically relevant fac- phate-buffered saline (five separately isolated popula-
tors that influence the biology of cells used for cardiac tions of male and female cells) were injected into the
therapy is especially important to optimize clinical trans- left ventricular free wall of male or female mdx mice
lation. (12–16 weeks of age, N = 6–12 animals per MDSC
Our laboratory has recently shown that female MDSCs population). Two weeks after injection, the mice were
are superior to male cells for repairing skeletal muscle sacrificed, the hearts harvested and flash-frozen in liquid
(10). Transplantation of wild-type female cells resulted nitrogen-cooled 2-methylbutane, and then cryosectioned
in greater number of dystrophin+ myocytes in the gas- to 10 µm thickness.
trocnemius muscle of mdx mice (model for Duchenne
Cell Transplantation to Infarcted Myocardiummuscular dystrophy lacking expression of dystrophin),
regardless of the sex of the recipient (10). Female recipi- Fifty male immunodeficient C57BL/6J-Prkdcscid mice
were bred for the current study. Infarcted mice were ran-ents were also shown to have more dystrophin+ myo-
cytes after transplantation than male recipients with domly allocated by a blinded investigator between the
treatment groups (saline, female MDSCs, or male MDSCs),either cell sex. When exploring MDSC-induced osteo-
genesis, male MDSCs displayed more robust osteogenic and 3 × 105 cells total in 30 µl saline were injected into
the left ventricular free wall of male SCID mice (13–16and chondrogenic differentiation in vitro and in vivo
versus female cells, regardless of the sex of the recipient weeks of age) 5 min after the permanent ligation of the
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left coronary artery (25,27). Six weeks after cell injec- area of collagen in five sections per heart normalized to
total muscle area within the section using ImageJ soft-tion, echocardiography was performed by a blinded in-
vestigator on the left ventricular short axis view at the ware (NIH).
midpapillary muscle level as described previously (25,
Staining for Cardiac-Specific Markers27) to assess cardiac function, and the mice were eu-
thanized and the hearts harvested, flash-frozen in 2- Sections from mdx samples were stained with rabbit
anti-dystrophin primary antibody (1:400; Abcam) andmethylbutane, and cryosectioned (25,27).
Alexafluor 488 donkey anti-rabbit secondary antibody
Engraftment (1:300; Molecular Probes) and goat anti-cardiac tropo-
nin I (1:25,000; Scripps) with rabbit anti-goat Alex-Cryosections were fixed in 4% paraformaldehyde and
then stained to determine donor cell engraftment. For the afluor 555 (1:200; Molecular Probes). Sections from the
infarcted samples were stained with mouse anti-fsMHCnoninjury model in mdx mice, the number of dystrophin+
myocytes was determined as described previously (9, (1:400; Sigma) and Alexafluor 488 donkey anti-mouse
secondary antibody (1:300; Molecular Probes) and goat15). Briefly, sections were stained for dystrophin with a
rabbit anti-dystrophin primary antibody (1:400; Abcam) anti-cardiac troponin I (1:25,000; Scripps) with rabbit
anti-goat Alexafluor 555 (1:200; Molecular Probes) andand Alexafluor 488 donkey anti-rabbit secondary anti-
body (1:200; Molecular Probes). Nuclei were revealed the number of double-positive cells were counted in
three high powered fields per heart.with 4′6-diamidino-2-phenylindol (DAPI) stain (100 ng/
ml; Sigma) and sections were mounted with Gel Mount
Analysis of Angiogenic Factor SecretionAqueous Mounting Medium (Sigma). The engraftment
capacity was determined by counting the number of Five male and female MDSC populations were plated
in PM at 50,000 cells/well in six-well collagen type 1-dystrophin+ fibers. In the infarction model, heart sections
were stained with mouse anti-fast skeletal myosin heavy coated plates. Twenty-four hours later, the medium was
switched to DMEM with 1% penicillin/streptomyocin.chain (fsMHC) antibody (1:400; Sigma) and Alexafluor
555 donkey anti-mouse secondary antibody (1:300; Mo- Cells were then cultured for an additional 24 h and the
medium was collected and flash-frozen until analysis.lecular Probes) to examine engraftment of the different
cell populations. Engraftment was determined by assess- ELISA for mouse VEGF (R&D Systems) was performed
according to manufacturer’s instructions and as pre-ing the area of fsMHC+ cells normalized to the area of
the entire muscle section (9). viously described (27). The VEGF levels were normal-
ized to cell number as measured by hemocytometer.
Identification of Endothelial Cells Within
the Engraftment of Transplanted Cells Cell Survival Following Oxidative Stress
Cells were plated in PM at 1,000 cells/well in a 24-The number of CD31+ cells in the engraftment area
was determined by double-staining tissue sections with well collagen type 1-coated plate. Twenty-four hours
later, the media was switched to PM with propidiumrat anti-CD31 primary antibody (1:300; Sigma) and rab-
bit anti-dystrophin primary antibody (1:400; Abcam), iodide (PI, 1:500, Sigma) or PM containing 350 µM hy-
drogen peroxide with PI. The plates were then placedand Alexafluor 488 donkey anti-rabbit secondary anti-
body (1:200; Molecular Probes) and Alexafluor 555 onto a previously described live cell imaging system
(Automated Cell, Inc), and fluorescent and brightfielddonkey anti-rat secondary antibody (1:300; Molecular
Probes) for the mdx mouse model. The rat anti-CD31 images were taken every 10 min in three fixed locations
per well. These images were analyzed using Image-primary antibody (1:300; Sigma) and mouse anti-fsMHC
antibody (1:400; Sigma) were used for the infarcted sam- Viewer software (ACI). Cell proliferation was deter-
mined by counting the number of cells present in theples (25,27,28). Blood vessel formation within the cell-
injected areas was determined by the number of CD31+ brightfield images at 12-h time points for 60 h. Cell sur-
vival was determined by counting the number of PI-pos-cells associated with dystrophin+ cells for the mdx model
or fsMHC+ cells for the infarction model. itive cells in the fluorescent images at each 12-h time
point.
Collagen Staining
MicroscopyInfarcted heart sections were fixed with 1% gluteral-
dehyde for 2 min and stained with the Masson Modified Florescence and brightfield microscopy were per-
formed using either a Nikon Eclipse E800 microscopeIMEB Trichrome Stain Kit (IMEB, CA, USA). Tri-
chrome staining was performed according to the manu- or Leica DMIRB inverted microscope equipped with a
Retiga digital camera and Northern Eclipse softwarefacturer’s guidelines and as previously described (25,
27). The sections were then assessed for the percentage (version 6.0, Empix). Image analysis was performed us-
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ing Northern Eclipse software or Image J software (Fig. 2A and B). There was no difference between male
and female cells (male cells: 17 ± 3 CD31+ structures,(available from NIH).
female cells: 14 ± 2, Fig. 2A). No differences were
Statistical Analysis noted between the sex of the MDSCs or recipient with
respect to the number of CD31+ structures in theData are summarized as mean and SD. Statistically
dystrophin+ areas (male cells: 17 ± 3, female cells: 13 ±significant differences between groups were determined
2, p = 0.26, male recipient: 15 ± 3, female recipient: 14 ±using a t-test for mdx studies (Microsoft Excel) or one-
3, p = 0.725, Fig. 2B). We also noted no correlation be-way or two-way ANOVA (SigmaStat) as appropriate for
tween the density of dystrophin+ myocytes and the num-the infarction model. In the event significant differences
ber of endothelial cells (endothelial cells in high dys-were detected using ANOVA, the appropriate multiple
trophin+ regions: 17 ± 3, endothelial cells in low dystrophin+comparisons test was used for post hoc analysis (Tukey
regions: 12 ± 2, p = 0.23, Fig. 2B). Thus, angiogenesistest).
within the implanted region did not appear to be affected
RESULTS by the sex of MDSCs and recipient mice or the effi-
ciency of engraftment of MDSCs.Sex-Related MDSC Fate Following Implantation
Into the Nonischemic mdx Heart
Sex-Related MDSC Fate in a Myocardial Infarct Model
Survival and Engraftment of MDSCs in the mdx
Cardiac Function. We measured cardiac function us-Heart. To determine whether cell and recipient sex
ing transthoracic echocardiography in SCID mice 6were critical determining factors in engraftment effi-
weeks following myocardial infarction and MDSC im-ciency of dystrophin+ cells in the myocardium, five male
plantation. Animal groups were divided into recipientsand five female MDSC populations were injected into
treated with male MDSCs, female MDSCs, or salinethe hearts of both male and female mdx mice. Two
alone. We noted no difference in left ventricular frac-weeks after cell transplantation, dystrophin+ myocytes
tional area change (FAC) between cell-injected heartswere observed within the hearts of all animals injected
based on MDSC sex; however, male and female cellswith MDSCs (Fig. 1A and B). The regeneration index
were significantly better than saline controls (23.2 ±(RI) revealed variability in MDSC engraftment in car-
1.3% for male cells, 21.5 ± 1.1% for female cells, anddiac muscle, with cell populations varying between ap-
13.1 ± 0.8% for saline, p < 0.05) (Fig. 3A). Postinfarc-proximately 100 to over 2,000 dystrophin+ cells. Sex-
tion fractional shortening (male cells: 20.6 ± 1.2%, fe-matched experiments showed no sex-based difference in
male cells: 19.1 ± 0.5%, and saline: 14.4 ± 0.8%), an-RI. Male cells/recipients had 1,309 ± 295 dystrophin+
other measure of left ventricle (LV) contractility, andcells and female cells/recipients had 1,010 ± 181 dystrophin+
end diastolic area, which measures dilatation of the heartcells. Sex of the recipient also showed no preferential (male cells: 15.0 ± 0.7 mm2, female cells: 14.6 ± 0.6 mm2,effect on MDSC engraftment within the heart: 1,086 ±
and saline: 17.8 ± 1.3 mm2, p < 0.05) (Fig. 3B) displayed172 dystrophin+ fibers in male recipients versus 1,069 ±
similar trends.146 dystrophin+ fibers in female recipients (Fig. 1C).
Cardiac Scar Tissue Remodeling. The amount ofWhen the sex of the cell was matched with that of the
collagen formed following myocardial injury influenceshost, the number of dystrophin+ myocytes was slightly
systolic and diastolic function as well as functional re-increased (sex matched: 1,167 ± 178, sex mismatched:
covery (35). Using standard measures of cardiac scar838 ± 107, p = 0.12). Very low levels of differentiation
formation (collagen staining by Masson’s trichrome andof implanted MDSCs toward a cardiac phenotype, aver-
calculation of the ratio of healthy LV to LV scar), weaging less than 1% of injected cells, were seen with all
noted that saline-injected hearts had very large scar tis-MDSC populations, regardless of sex or number of
sue area ratios 6 weeks following myocardial infarctiondystrophin+ myocytes, which is consistent with pre-
(65.0 ± 5.1%) (Fig. 4). MDSCs were found to have su-viously published results (25,28). Overall, there was no
perior engrafting abilities compared with saline injected;difference in the number of engrafted dystrophin+ myo-
however, sex did not influence postinfarction scar inhi-cytes based either on the sex of the MDSCs or the sex
bition, as all cell-injected groups had significantlyof the recipient.
smaller scar tissue area ratios (male cells: 35.2 ± 5.4%,Sex Does Not Influence Vascularization of MDSCs in
Fig. 4B; female cells: 35.7 ± 6.9%, Fig. 4C; p < 0.05the mdx Heart. MDSC implantation triggers angiogen-
compared to saline, Fig. 4D).esis during cardiac remodeling following injury (25,27).
At 2 weeks post-cell transplantation, we measured the Sex-Related MDSC VEGF Secretion. We determined
VEGF secretion into cell culture supernatant for 24 hnumber of endothelial cells within the dystrophin+ cell
engraftment zones for all animals injected with MDSCs of serum starvation due to the critical role of VEGF in
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Figure 1. Engraftment in muscular dystrophy model. (A, B) Representative images of dystrophin
stain showing both low (A) and high (B) engraftments of dystrophin+ myocytes. Scale bar: 100
µm. (C) Number of dystrophin+ myocytes in each group, showing that there is no sex difference
based on cell or host sex.
Figure 2. Blood vessel formation in the heart in muscular dystrophy model. (A) No significant difference in blood vessel formation
in the engraftment of dystrophin+ myocytes is seen with cell sex alone or (B) cell sex and recipient sex. (C) Representative image
showing blood vessels within the dystrophin+ myocytes (scale bar: 50 µm). Blue: DAPI, red: CD31, green: dystrophin.
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Figure 3. Cardiac function in ischemic heart. No difference is seen between the sexes in terms of
cardiac function. When looking at fractional area change, all groups were significantly better than
the saline control group (p < 0.05) (A). The same trend was seen with end diastolic area, with
both male and female cell-injected hearts displaying less dilatation than saline (p < 0.05) (B).
postinfarction angiogenesis. No difference in VEGF se- characteristics in response to oxidative stress (Fig. 6),
which correlates to the similar levels of survival and car-cretion between male and female MDSCs was noted (male:
623 ± 200 pg/ml/106 cells, female: 752 ± 143, p = 0.58) diac engraftment for male and female cells seen in vivo
in both the mdx and myocardial infarction (MI) mouse(Fig. 5A). When subjected to oxidative stress after treat-
ment with hydrogen peroxide, all cells increased their models.
production of VEGF, regardless of cell sex (male cells: Donor Cell Engraftment and Differentiation. We
1,387 ± 389 pg/ml/106 cells, female cells: 1,240 ± 233). noted a lack of difference in the degree of MDSC en-
Angiogenesis. No difference in blood vessel forma- graftment in postinfarction SCID LV myocardium based
tion was noted in the engraftment areas based on MDSC on the sex of implanted MDSCs at 6 weeks (male cells:
sex (male cells: 10 ± 1 CD31+ structures, female cells: 27.2 ± 3.8%, female cells: 25.2 ± 3.9%) (Fig. 6B). As
11 ± 1, p = 0.37) (Fig. 5B). Outside of the engraftment noted in previous studies, we found less than 1% of im-
area, there was again no difference between MDSC planted MDSCs expressed cardiac markers (male cells:
sexes. However, there was a trend that MDSC injection, 0.2 ± 0.2%, female cells: 0.3 ± 0.1%), with the vast ma-
regardless of cell sex, induced greater levels of neovas- jority maintaining expression of skeletal muscle markers
cularization than saline injection at the 6-week time (25,27). The engraftment and regeneration seen in the
point (PBS: 34 ± 4 CD31+ structures, male cells: 43 ± 7, infarction model differed from the noninfarcted mdx
female cells: 54 ± 9) (Fig. 5C). These results support the model, and that is likely due to the time points exam-
role for MDSCs in inducing neovascularization versus a ined, the different number of injected cells, and presence
recipient response. of injury in the infarction model.
Cell Survival After Oxidative Stress. MDSCs have a
DISCUSSIONsuperior ability to survive oxidative stress compared to
myoblasts (25), and this seems to be related to the higher Cell transplantation is considered to be a potential
therapy for cardiac repair after injury; however, there isregeneration capacity in skeletal and cardiac muscle.
Both male and female MDSCs display similar survival still debate as to how the repair takes place and what
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factors play a critical role. Some groups have demon- we hypothesize that this difference may be due to the
different muscle environment found in the heart, includ-strated that stem cells can differentiate into cardiomyo-
cytes in situ (19), thereby enacting repair, whereas oth- ing cyclic mechanical strain and the biochemical make-
up of infarcted myocardium. We have demonstrated thaters have shown that paracrine mechanisms provide
cardioprotection (32,34). Up until recently, cell sex was transplantation of both male and female murine MDSCs
attenuated functional deterioration after myocardial in-not a factor for consideration in cell transplantation, and
results seem to be dependent on injury model, cell type, farction, and we observed that cardiac repair using
MDSCs does not appear to be dependent on cell sex.and time points examined (4,6). Previous results from
our laboratory indicate that cell sex should be consid- There was no difference when examining cardiac func-
tion after cell transplantation, engraftment capacity, scarered for muscle, cartilage, and bone regeneration. These
experiments demonstrated that female MDSCs are better tissue formation, or coexpression of cardiac phenotype
and induction of angiogenesis between the male and fe-at engrafting into skeletal muscle, while male cells are
more osteogenic and chondrogenic (5,10). Other groups male cells. These results suggest that the recovery of
postinfarction LV function following MDSC implanta-have shown that cell sex is also a factor with mesenchy-
mal stem cell activation and cardiac repair, with female tion is not due to MDSC sex.
The classic idea for the mechanism of cardiac cellcells improving heart function to a greater extent (6,7).
Based on these results, we hypothesized that female therapy is that delivery of the appropriate stem cells
would repair the damaged heart via active myocardialmuscle-derived cells would be superior for cardiac re-
pair. regeneration from transdifferentiation of the adminis-
tered stem cells to the cardiac lineage (24). However,We observed no difference in the mdx model in the
engraftment capacity of MDSCs in the heart based on increasing evidence has led to the recognition of another
mechanism of cardiac repair: the paracrine effect. In linesex. This result is in contrast to previously reported re-
sults on MDSC transplantation into skeletal muscle, and with this mechanism, MDSCs seem to enact repair
Figure 4. Scar tissue area fraction. (A, B, C) Representative images of Masson Trichrome stains (collagen: blue, muscle: red) (A)
saline-injected group, (B) male MDSC-injected group, and (C) female MDSC-injected group. Thinner walls and increased collagen
content are visible in the saline-injected group. (D) No difference between the cell-injected groups, although all cell-injected hearts
had significant lower levels of scar than the saline control (p < 0.05).
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differentiate into cardiomyocytes to increase heart func-
tion after injury, and this leads to the hypothesis that
sex-based differences in MDSCs may only be seen when
differentiation toward a specific lineage is required. This
idea is supported by sex differences observed with
MDSC transplantation for skeletal muscle, where the
cells had to differentiate toward skeletal muscle lineages
to promote the healing process.
There are many issues to consider when examining
the influence of sex on stem cell potential, particularly
for cardiac repair. Intrinsic and extrinsic cellular mecha-
nisms regulate the balance of self-renewal and differen-
tiation in stem cells (21). Although we did not find sex
differences with MDSCs for cardiac repair, other groups
have shown that source sex is relevant for mesenchymal
stem cells (6). Although it was not examined in the mes-
enchymal paper, we cannot exclude the possibility that
a sex difference was seen with these cells due to differ-
ential differentiation toward a cardiac phenotype. In our
current study, we implanted MDSCs isolated from 3-
week-old mice, which could have influenced the results,
although cells of the same age were used for previous
sex studies in skeletal muscle, cartilage, and bone with-
out negative effect.
Figure 5. VEGF secretion and angiogenesis in infarcted heart.
(A) VEGF secretion into cell culture supernatant demonstrated
no sex-based difference. (B) At 6 weeks, no difference in
blood vessel formation is seen in the fsMHC+ myocytes based
on cell sex (N = 9–10 per group). (C) Outside of the engraft-
ment areas, both male and female cells had induced more
blood vessels than saline controls, but the difference was not
significant.
through paracrine mechanisms by increasing survival
and repair of the recipient cardiac tissue rather than
by differentiating into cardiomyocytes. Regeneration of
cardiac tissue without cardiac differentiation has also
been seen with bone marrow and hematopoietic stem
cells used to treat ischemia reperfusion injuries and
myocardial infarctions (22,34). Previous results have
highlighted the importance of VEGF secretion in cardiac
repair (27), and because both male and female MDSCs
secrete similar levels of VEGF, this could help recon-
cile, at least in part, the lack of a sex difference seen in
terms of capillary density in this study. When treating Figure 6. Cell survival under oxidative stress and area of
fsMHC+ myocytes in infarcted heart. (A) No difference wasischemic heart disease, perfusion of the affected tissue
seen in the survival of male and female MDSCs in vitro afteris an essential part of any therapy. The improved regen-
treatment with hydrogen peroxide (350 µM). Proliferation
erative capabilities of MDSCs might be attributed to rates were comparable between the sexes (data not shown).
higher expression levels of antioxidants or increased (B) No difference is seen in engraftment at 6 weeks between
cell sex or area of fsMHC+ myocytes.VEGF production (27). In the heart, cells do not need to
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